b-Catenin, a structural component of cell-cell adhesions, is also a potent signaling molecule in the Wnt pathway activating target genes together with Lef/Tcf transcription factors. In colorectal and many other types of cancer, b-catenin is hyperactive owing to mutations in b-catenin, or in components regulating b-catenin degradation. Deregulated b-catenin can cause the activation of p53, a key tumor suppressor mutated in most cancers. Activated p53 can feed back and downregulate b-catenin. Here we investigated the mechanisms involved in downregulation of b-catenin by p53. We found that the p53-mediated reduction in b-catenin involves enhanced phosphorylation of b-catenin on key NH 2 -terminal serines and requires CK1 and GSK-3b activities, both being components of the b-catenin degradation machinery. Mutations in these NH 2 -terminal b-catenin serines blocked the ability of p53 to enhance the turnover of b-catenin. p53 also induced a shift in the distribution of the scaffold molecule Axin to a Triton X-100-soluble fraction, and led to depletion of b-catenin from this Triton-soluble fraction. The majority of Axin and phosphorylated b-catenin, however, colocalized in Triton X-100-insoluble punctate aggregates near the plasma membrane, and kinetics studies indicated that in the presence of p53 the movement of Axin into and out of the Triton X-100-insoluble fraction is accelerated. These results suggest that p53 induces a faster mobilization of Axin into the degradation complex thereby enhancing b-catenin turnover as part of a protective mechanism against the development of cancer.
Introduction b-Catenin is a major component of the cytoplasmic plaque of cell-cell adherens junctions linking cadherin family cell adhesion receptors to the actin cytoskeleton (Kemler, 1993; Ben-Ze'ev and Geiger, 1998) . In addition, b-catenin plays a key role in transduction of the Wnt signal by activating target gene expression in complex with Lef/Tcf transcription factors (Willert and Nusse, 1998) . A critical step in the regulation of Wnt signaling involves the control of b-catenin degradation. In the absence of Wnt signaling, b-catenin is efficiently targeted for degradation by a multiprotein complex including the scaffold proteins Axin/conductin, the serine/threonine kinase glycogen synthase kinase 3b (GSK-3b) and the adenomatosis polyposis coli (APC) tumor suppressor protein (Peifer and Polakis, 2000) . A priming phosphorylation of b-catenin on serine 45, by caseine kinase 1 (CK1) (Amit et al., 2002; Liu et al., 2002; Yanagawa et al., 2002) , is suggested to precede its further phosphorylation on NH 2 -terminal serines and a threonine by GSK-3b that earmarks b-catenin for degradation by the ubiquitin-proteasome system (Hart et al., 1999; Winston et al., 1999) . Activation of the canonical Wnt pathway includes the inhibition of GSK3b-mediated phosphorylation of b-catenin that blocks its subsequent proteasomal degradation, leading to nuclear accumulation of b-catenin and transcriptional activation of Tcf/Lef-responsive target genes (Behrens et al., 1996; Huber et al., 1996; Molenaar et al., 1996) . bCatenin signaling operates at multiple stages during embryogenesis (Cadigan and Nusse, 1997) , and aberrant activation of b-catenin signaling is a characteristic step in the early stages of colorectal carcinoma and other types of cancer (Bienz and Clevers, 2000; Polakis, 2000; Conacci-Sorrell et al., 2002) . Such activation results from the accumulation of b-catenin in the nuclei of cells owing to mutations in components regulating its degradation (Axin/conductin or APC), or by stabilizing mutations in the NH 2 terminus of b-catenin Morin et al., 1997) . Constitutive activation by b-catenin-Tcf/Lef complexes of target genes such as cyclin D1 Tetsu and McCormick, 1999) and c-myc (He et al., 1998) , which provide growth advantage to cells, is believed to contribute to the onset of oncogenesis.
A possible crosstalk between b-catenin and p53 pathways during cancer progression has long been suggested, most notably in human colorectal cancers displaying aberrant b-catenin signaling and a high frequency of mutations in the major tumor suppressor p53 (Kinzler and Vogelstein, 1996) . Recent studies have indicated a more direct link between b-catenin and the p53 protein by demonstrating that deregulated b-catenin can induce the stabilization of p53 leading to activation of p53 target genes (Damalas et al., 1999) . The increase in p53 is regulated by ARF, which blocks the proteasomal degradation of p53 mediated by Mdm2 (Damalas et al., 2001) . The elevation in p53 elicits an antiproliferative response that is suggested to serve as a protective mechanism against the development of cancer (Oren et al., 2002; Oren, 2003) . Interestingly, the increase in p53 levels, elicited by either genotoxic stress or overexpression, not only blocks cell proliferation induced by b-catenin but also downregulates b-catenin in a variety of cell types, thus forming a negative feedback loop (Sadot et al., 2001) . The underlying mechanism apparently involves enhanced proteasomal degradation of b-catenin by p53 target genes, and is either mediated by GSK-3b (Sadot et al., 2001) or by a GSK-3b-independent mechanism (Liu et al., 2001; Matsuzawa and Reed, 2001) .
In the present study we addressed the mechanisms involved in p53-mediated downregulation of b-catenin and found that it requires both Ser45 priming phosphorylation and GSK-3b-dependent phosphorylation. We also provide evidence for faster recycling of an Axin-based b-catenin degradation complex in the presence of p53.
Results

Siah-1 and PTEN are not required for p53-mediated downregulation of b-catenin levels
Recent studies have demonstrated that increased p53 levels can downregulate the level of b-catenin and its signaling activity, without a direct interaction between p53 and b-catenin (Liu et al., 2001; Matsuzawa and Reed, 2001; Sadot et al., 2001) , indicating that this process may involve p53 target genes. Since proteins encoded by the p53-inducible genes Siah-1 (Amson et al., 1996; Matsuzawa et al., 1998) and PTEN (Stambolic et al., 2001) were shown to be capable of reducing the level of b-catenin (Liu et al., 2001; Matsuzawa and Reed, 2001; Persad et al., 2001) , we examined if they are involved in the p53-mediated downregulation of bcatenin in HEK-293 cells. Transfection of either Siah-1 (Figure 1b) or PTEN (Figure 1c ) effectively reduced the levels of cotransfected wt b-catenin in these cells, as does transfection with p53 ( Figure 1a) .
To test whether Siah-1 or PTEN are responsible for the p53-mediated decrease in b-catenin, we employed the siRNA approach. Using siRNA for PTEN and Siah-1, we showed that they were effective in downregulating transfected Siah-1 (Figure 1d ) and PTEN ( Figure 1e ) in 293 cells. Since Siah-1 is a very unstable protein, rapidly degraded by the proteasome (Hu and Fearon, 1999) , Siah-1-transfected cells were treated with the proteasome inhibitor MG132 to obtain detectable levels of this protein (Figure 1d ). Cotransfection of p53 with siRNA for Siah-1 or PTEN had no effect on the ability of p53 to reduce the level of b-catenin (Figure 1f and g, compare lane 3 to lane 2, respectively). In contrast, siRNA to p53 was effective in blocking the p53 effect on b-catenin levels (Figure 1h , compare lane 3 to lane 2).
We concluded that while Siah-1 and PTEN can each downregulate b-catenin, they are not required for the p53-mediated effect on b-catenin level in 293 cells.
p53-mediated downregulation of b-catenin involves GSK3b and enhanced phosphorylation of b-catenin on Ser33 and Ser37
Since previous studies suggested that the p53-induced downregulation of b-catenin in 293 cells involves GSK3b (Sadot et al., 2001) , we examined in more detail if bcatenin phosphorylation is required for its p53-induced degradation. First, we confirmed the requirement for GSK-3b in this p53-mediated regulation by showing that LiCl, which inhibits GSK-3b activity, can block the ability of p53 to downregulate b-catenin (Figure 2a , compare lane 4 to lane 3; Sadot et al., 2001) . Next, we demonstrated that b-catenin proteins mutant in key serines at the NH 2 terminus of b-catenin (the GSK-3b phosphorylation sites Ser33, Ser37 and Thr41) were resistant to p53-mediated downregulation (Figure 2b , compare lanes 4 and 6 to lanes 3 and 5), in contrast to wt b-catenin (Figure 2b , lanes 1 and 2). Using an antibody against phosphoserine 33/37-b-catenin, we could show a p53-mediated increase in b-catenin phosphorylation on these serines, presumably by GSK-3b (Figure 2c , compare lane 2 to lane 1). The faint higher molecular weight bands, recognized by the anti-p33/37-b-catenin antibody, most probably represent ubiquitylated forms of b-catenin (Sadot et al., 2001) . We also examined whether the enhanced phosphorylation of b-catenin in the presence of p53 involves an increase in GSK-3b levels, but did not detect a significant change (Figure 2d ). Since GSK-3b activity can be inhibited by phosphorylation on Ser9, we examined if there are changes in Ser9 phosphorylation of GSK-3b using anti-phosphoserine 9-GSK-3b antibody, but no detectable changes in GSK-3b Ser9 phosphorylation were observed (Figure 2d) .
Recent studies have shown that b-catenin degradation involves a priming phosphorylation step on Ser45 by CK1 (reviewed in Polakis, 2002) . We found that an S45F substitution b-catenin mutant was refractory to p53-induced degradation, suggesting that Ser45 priming phosphorylation is essential for p53-induced degradation of b-catenin (Figure 2b, lanes 7 and 8) .
In a recent report, activation of p53 was suggested to result in a direct interaction with, and activation of, GSK-3b in the nuclei of cells and a decrease in b-catenin level (Watcharasit et al., 2002) . In addition, a nuclearcytoplasmic transport of b-catenin, by a process involving APC, was also implicated in b-catenin degradation (Henderson, 2000; Rosin-Arbesfeld et al., 2000) . We therefore examined whether this nucleocytoplasmic transport of b-catenin is involved in its degradation by activated p53. We employed a chimeric b-catenin construct containing, at its NH 2 terminus, the transmembrane and cytoplasmic domains of the interleukin-2a receptor, linked to full-length b-catenin and a GFP tag at the COOH terminus (Figure 3a) . This b-catenin chimera, when introduced into cells, was sequestered to the outer cell membrane and cytoplasmic Simcha et al., 1998) . Since the majority of transfected HA-p53 remained in the nuclei when cotransfected with either wt or the IL2-b-catenin chimera (data not shown), we concluded that the exclusive cytoplasmic localization of b-catenin does not interfere with the ability of p53 to mediate its degradation.
Altered distribution and dynamics of Axin in cells overexpressing p53
The studies presented above demonstrated that while inhibition of GSK-3b blocked the effect of p53 on bcatenin degradation and abolished the p53-enhanced phosphorylation of b-catenin on Ser33/37, no changes in GSK-3b level or its Ser9 phosphorylation were observed in p53-overexpressing cells (Figure 2d ). The rate of NH 2 -terminal b-catenin phosphorylation by GSK-3b is determined by the assembly of GSK-3b and b-catenin on an Axin-based scaffold (Zeng et al., 1997; Hart et al., 1998; Ikeda et al., 1998) , and by In contrast, p53 had no effect on the distribution of GSK-3b that was mostly found in the Triton X-100-soluble fraction (Figure 4d ). Together, these results suggest that while p53 had no effect on total Axin levels, it induced a shift in Axin to the Tritonsoluble pool (that contains the free pool of b-catenin designated for degradation) and this correlated with a reduction in b-catenin levels in this subcellular fraction.
To determine the cellular localization of the Axin/ CK1/GSK-3b/b-catenin degradation complex, we analysed the distribution of p45-and p33/37-b-catenin forms, since the phosphorylation on both Ser45 and Ser33/37 occurs in this complex. At 24 h after transfection with b-catenin, or with b-catenin and p53, cells were treated with MG132 for different time periods (between 0 and 180 min) to block proteasomal degradation and allow a detectable accumulation of phospho-b-catenin ( Figure 5 ). The cells were fractionated into Triton X-100-soluble and -insoluble fractions and equal volumes of these extracts were analysed by Western blotting with antibodies for p45-and p33/37-b-catenin. Surprisingly, while transfected b-catenin was evenly distributed between the Triton-soluble and -insoluble fractions, in both control and p53-transfected cells (Figure 5a , compare lanes 1-6 to lanes 7-12 for HA-b-cat), the phosphorylated forms of b-catenin on either serines 33/ 37 or serine 45 were exclusively localized in the Triton X-100-insoluble fraction (Figure 5a , lanes 7-12 for p45-b-cat and p33/37-b-cat). Quantitative analysis of the kinetics of phospho-b-catenin accumulation after MG132 treatment indicated that both p45-b-cat ( Figure 5b ) and p33/37-b-cat (Figure 5c ) accumulated significantly faster in p53-transfected cells, in accordance with the enhanced degradation of b-catenin induced by p53.
While enhanced b-catenin degradation in the presence of p53 correlated with an increase in Axin and depletion of b-catenin from the Triton-soluble fraction, the phosphorylated forms of b-catenin were exclusively does not affect the level of total GSK-3b or the Ser9-phosphorylated form of GSK-3b. Cells were transfected with HA-p53 or with a control empty vector, and 24 h after transfection the blots were probed with anti-GSK-3b and anti-phospho-GSK-3b (Ser9) antibodies Downregulation of b-catenin by p53 E Levina et al found in the Triton-insoluble fraction. To reconcile these apparently contradictory observations, we propose that an early stage in b-catenin degradation (recruitment of the soluble pool of b-catenin into an Axin-based degradation complex) occurs in the Triton-soluble fraction (Figure 7 ). Further maturation of this degradation complex (involving recruitment of CK1 and GSK-3b) leads to relocalization of the Axin complex into a Triton-insoluble pool where b-catenin phosphorylation takes place. This implies that inhibition of GSK-3b activity by LiCl should not interfere with Axin-dependent scaffolding, its transition to the Triton-insoluble fraction or Ser45 phosphorylation of b-catenin by CK1. In support of this view, we found that treatment with LiCl led to an increase in Ser45 phosphorylation of b-catenin ( Figure 6A , d compare to 6A, c) and relocalization of Axin from small and punctate cytoplasmic structures ( Figure 6A, a) into larger aggregates in proximity of the plasma membrane ( Figure 6A, b) . In LiCl-treated cells, p45-b-catenin was also organized in structures at the cell periphery ( Figure  6A, d ), similar to those seen for Axin ( Figure 6A, b) . In p53-transfected cells treated with LiCl, a similar reorganization was evident (data not shown). This was expected, since phosphorylated b-catenin was found in the Triton X-100-insoluble fraction in both control and p53-overexpressing cells (Figure 5a , compare lanes 10-12 to lanes 7-9). The total level of Axin was not changed by LiCl treatment in the presence of p53 ( Figure 6B ), but we observed a depletion of Axin from the Tritonsoluble fraction ( Figure 6B , compare lanes 10 and 11 to lane 8). Next, we determined the kinetics of Axin transition from the Triton X-100-soluble fraction into the -insoluble fraction and then back to the Triton-soluble fraction. For this, 293 cells were treated with LiCl for various time periods (0-180 min), to block the GSK-3b phosphorylation step, then LiCl was washed away and the cells were incubated in fresh medium for different times (0-180 min). The Triton X-100-soluble fraction and, from parallel cultures, total cell lysates were prepared from both control and p53-transfected cells, and the level of Axin was determined ( Figure 6B) . Analysis of the quantitative changes in the decrease of Triton-soluble Axin after LiCl treatment and its recovery after LiCl removal (after normalizing to the total level of Axin and tubulin) indicated that both were significantly faster in p53-transfected cells ( Figure 6C ). We concluded that the assembly and disassembly of the Triton-insoluble Axin complex (that mediates bcatenin phosphorylation) were both enhanced by p53. 
Discussion
This study aimed to address the molecular mechanisms underlying the downregulation of b-catenin levels by p53. The interplay between b-catenin and p53 is quite complex. Similar to other oncogenes, b-catenin induces an ARF-dependent accumulation of p53 (Sherr and Weber, 2000; Damalas et al., 2001) . Interestingly, the p53-mediated protective response to oncogenic b-catenin involves, in addition to growth arrest, a p53-dependent downregulation of b-catenin signaling by enhancing b-catenin degradation. Activation of p53 by genotoxic stress, or its overexpression in cells, leads to increased degradation of b-catenin by the ubiquitinproteasome system (Liu et al., 2001; Matsuzawa and Reed, 2001; Sadot et al., 2001) . This effect of p53 on bcatenin is believed to involve transcriptional activation of p53-responsive target genes that can promote the accelerated degradation of b-catenin. Since expression of the p53 target genes Siah-1 and PTEN was recently shown to reduce the levels of b-catenin (Matsuzawa and Reed, 2001; Persad et al., 2001) , we examined whether they are responsible for the decrease in b-catenin following overexpression of p53 in HEK-293 cells. While we could demonstrate that Siah-1 and PTEN can both reduce the level of wt b-catenin in these cells, siRNA against these genes did not affect the enhanced degradation of b-catenin in response to p53 expression, suggesting that they are not required for this effect of p53 in HEK-293 cells (Figure 1 ). In contrast, blocking GSK-3b activity abolished the effect of p53 on b-catenin (Figure 2a; Sadot et al., 2001) , implying that this 1-7) . At 24 h after transfection, the cells were treated with LiCl (lanes 1-4, 8-11) for different times (0-180 min), washed and incubated for 0-180 min in the absence of [12] [13] [14] . Total cell lysates and Triton-soluble fractions (from parallel cultures) were subjected to Western blot analysis using anti-Axin antibodies. Tubulin served for loading control. (C) Quantification of Axin levels in the Tritonsoluble fraction. The level of Axin at 0 h was set as 100%. The bar in (A, d) is 10 mM Figure 7 Proposed model for p53-mediated degradation of bcatenin. p53 is suggested to affect the kinetics of Axin transition between the Triton X-100-soluble and -insoluble fractions. According to this model, Triton-soluble Axin recruits b-catenin from this soluble pool into the Triton-insoluble pool where the priming phosphorylation on Ser45 by CK1 is followed by GSK-3b-mediated phosphorylation on Ser33/37 and Thr41, followed by degradation of phosphorylated b-catenin by the ubiquitin-proteasome system. The rate of transition of Axin from the Triton-soluble to the -insoluble fraction and back to the Triton-soluble fraction is accelerated by activated p53 and results in enhanced b-catenin turnover Downregulation of b-catenin by p53 E Levina et al accelerated degradation of b-catenin proceeds through the classical GSK-3b degradation complex, as previously suggested (Sadot et al., 2001) . Since GSK-3b-mediated phosphorylation of the NH 2 terminus of b-catenin in the degradation complex requires a CK1-dependent priming phosphorylation of b-catenin on Ser45, we determined the requirement for such phosphorylation in the p53-mediated downregulation of b-catenin, and found that these phosphorylations are necessary (Figure 2) . Mutations in the CK1 or GSK3b phosphorylation sites of b-catenin abolished the p53 effect on b-catenin indicating that the dual CK1-GSK3b kinase system is involved in the degradation of b-catenin by activated p53. Using a specific antibody to phosphoserines 33/37 of b-catenin, we also detected an increase in NH 2 -terminal phosphorylation of b-catenin induced by p53. Next, we examined if the recently reported observation on the activation of nuclear GSK3b by p53 (Watcharasit et al., 2002) is responsible for the effect of p53 on b-catenin levels that we observed in the cell system we studied. By using a chimeric membrane-tethered b-catenin form we found that this cytoplasmically sequestered form of b-catenin is also effectively downregulated by p53, indicating that nuclear localization of b-catenin is not required for its enhanced downregulation by p53 in the HEK-293 cell system (Figure 3) .
Our analysis of GSK-3b levels and Ser9 phosphorylation showed that these remained unchanged after activation of p53, and therefore suggested that an upstream step, the assembly of the APC/CK1/GSK3b/Axin/b-catenin degradation complex, is probably the target affected by p53. Axin has been established as a central component of the b-catenin degradation complex and plays a key role in the CK1-mediated priming phosphorylation of b-catenin that precedes its further phosphorylation by GSK-3b (reviewed by Polakis, 2002) . Furthermore, recent structural studies based on co-crystallization of GSK-3b and a minimal GSK-3b-binding peptide of Axin revealed a more than 20 000-fold increase in GSK-3b-dependent phosphorylation of b-catenin following its interaction with Axin (Dajani et al., 2003) , thus pointing to the paramount scaffolding role of Axin in b-catenin degradation. While we did not detect a change in the total level of Axin in cells overexpressing p53, there was a significant shift in Axin into the Triton X-100-soluble fraction of such cells. This Triton-soluble fraction is believed to also contain the soluble pool of b-catenin designated for degradation. We found that both the endogenous and transfected Axin were enriched in the Triton-soluble fraction that became depleted of b-catenin in p53-overexpressing cells (Figure 4d ). Since the absolute majority of NH 2 -terminally phosphorylated b-catenin was localized in the Triton X-100-insoluble fraction (Figure 5a) , together with the majority of Axin, we hypothesize that Tritonsoluble Axin represents an early stage in b-catenin degradation involved in recruiting the soluble pool of b-catenin into the Axin-based degradation complex (Figure 7 ). In cells with activated p53, the release of Axin into the Triton-soluble pool is more efficient (Figure 6B and C) leading to an increase in Tritonsoluble Axin levels (Figure 4b and c) . While the underlying mechanism remains to be established, it might involve a more efficient GSK-3b phosphorylation of Axin in the presence of p53. In addition, the increased rate of Axin association with the Triton-insoluble fraction is also leading to a more efficient sequestration of soluble b-catenin into the degradation complex. This results in a more effective depletion of b-catenin from the Triton-soluble fraction (Figure 4d , lane 8, b-cat, and Figure 7 ). This hypothesis is supported by the kinetics experiments showing a faster accumulation of both CK1-and GSK-3b-phosphorylated forms of b-catenin in p53-transfected cells ( Figure 5) . In control cells, however, we observed a higher level of p45-b-catenin than in p53-transfected cells (Figure 5a , compare lane 7 to lane 10). We interpret this to mean that Ser45 phosphorylation of b-catenin by CK1 is faster than the following GSK-3b phosphorylation step that could be rate limiting. This will lead to the accumulation of p45-b-catenin 'waiting' to be phosphorylated by GSK-3b before degradation. According to this view, in p53-expressing cells, GSK-3b phosphorylation is faster, while Ser45 phosphorylation proceeds at the same rate, leading to decreased levels of p45-b-catenin. Therefore, in the presence of MG132, p45-b-catenin will accumulate owing to the constitutively high activity of CK1 as indicated in Figure 6A . In addition, in the presence of p53, there is less b-catenin than in control cells and consequently less p45-b-catenin ( Figure 6A , compare lanes 7 and 10).
By inhibiting GSK-3b activity with LiCl, but allowing the CK1-mediated phosphorylation of b-catenin on Ser45, we could demonstrate that Axin relocalizes from a dot-like diffuse pattern to a punctate organization at the cell periphery ( Figure 6A ). b-Catenin phosphorylated on Ser45 displayed a similar localization to these Axin-containing structures ( Figure 6A ). This is the first visualization of such colocalization of Axin with the initial step of b-catenin phosphorylation by CK1 on Ser45, in the absence of GSK-3b activity. We have also determined the kinetics of Axin mobilization into and out of the Triton-soluble fraction, when LiCl inhibited GSK-3b activity, and after LiCl was removed. Both the accumulation and the exit of Axin from the Triton X-100-soluble fraction proceeded with a faster kinetics in p53-overexpressing cells ( Figure 6B and C) . This implies that the faster kinetics in the recycling of the Axin complex between the Triton-insoluble fraction into the Triton-soluble fraction (Figure 7 ) in p53-overexpressing cells most probably results in enhanced assembly of the Axin complex that regulates b-catenin degradation. This change plays a key role in the mechanism responsible for enhanced b-catenin downregulation by p53 and makes Axin a novel molecular target of the p53 response to the oncogenic action of b-catenin.
Recent studies implicated that translocation of Axin between a soluble pool and a membrane-bound fraction is a key step in the induction of Wg/Wnt signaling that regulates Armadillo/b-catenin degradation during Drosophila development. This process is suggested to involve, in Drosophila, the Dsh/Dvl phosphoprotein, a crucial modulator of Wg/Wnt signaling (Cliffe et al., 2003) , and is apparently independent of GSK-3b (Tolwinski et al., 2003) . Thus, the cycling of Axin between different subcellular locations appears to be of a more general relevance in regulating the assembly of the b-catenin degradation complex. Future studies aimed to identify the proteins that bind to soluble Axin in the presence of p53 will determine if these include p53 target gene products, or p53 protein partners that could regulate the p53-dependent downregulation of b-catenin.
Materials and methods
Cells and transfections
HEK-293 cells were grown in DMEM and 10% bovine calf serum. For transfections, cells were plated to form 70-90% confluent cultures and were transfected using Lipofectamine (GIBCO BRL), or by the calcium phosphate method. Treatments with 30 mM LiCl, 30 mM NaCl or 25 mM MG132 (Calbiochem) were for the time periods indicated.
Plasmids
The following expression plasmids were employed: HAwt-p53, HA-wt-b-catenin, HA-S33Y-b-catenin (Sadot et al., 2001) , myc-S45F-b-catenin (Amit et al., 2002) , Flag-b-cateninmutant (33,37,41,454A) (Liu et al., 2002) and pEGFP-PTEN (Persad et al., 2001) . pCMV-myc-Axin was provided by Dr F Costantini (Columbia University, NY). The IL2-b-catenin construct contained the extracellular and transmembrane domains of the interleukin-2a receptor fused to mouse b-catenin and EGFP, and was prepared by M Shtutman (Shtutman et al., in preparation) . pBKRSV-Siah-1 (Roperch et al., 1999) was from Dr A Telerman (Molecular Engines Laboratories, Paris). The human Siah-1 was amplified by PCR using the following primers: 5 0 -ACCTGA ATTCTCAACA-CATGGAAATAGTTAC-3 0 and 5 0 -ACCTAGATCTAT-GAGCCGTCAGACTGCTAC-3 0 , containing XbaI sites. The amplified, full-length Siah-1 was introduced into the pCGN-HA expression vector (Simcha et al., 1998) , using the XbaI site. The sequence of the selected clone was verified by DNA sequencing. To produce siRNA for Siah-1 and PTEN, the corresponding stem-and-loop oligonucleotides for Siah-1, GATCCCCATGAGCCGTCAGACTGCTATTCAAGAGA-TAGCAGT CTGACGGCTCATTTTTTGGAAA, and for PTEN, GATCCCCCTATTCCAATGT TCAGTGGTTCAA-GAGACCACTGAACATTGGAATAGTTTTTGGAAA, were introduced into the pSUPER vector driven by the H1-RNA promoter (Brummelkamp et al., 2002) . To produce siRNA for p53, the same pSUPER vector was used.
Western blotting
The following antibodies were used: polyclonal anti-HA Y11 sc-805 (Santa Cruz Biotechnology), monoclonal anti-Myc 9E10, anti-GFP (a mixture of two mouse monoclonal antibodies, clones 7.1. and 13.1, Roche), monoclonal anti-atubulin DM1A (Sigma), polyclonal anti-b-catenin (Sigma), polyclonal anti-phospho-b-catenin (Ser33/37/Thr41) (Cell Signaling), polyclonal anti-phospho-b-catenin (Thr41/Ser45) (Cell Signaling), monoclonal anti-phospho-b-catenin (Ser33/37) clone BC-22 (Sigma), monoclonal anti-GSK-3b (BD Transduction Laboratories) and polyclonal anti-phospho-GSK-3a/b (Ser21/9) (Cell Signaling). Polyclonal anti-Axin antibodies (against aa 288-514) were obtained from Dr R Nusse and K Willert (Stanford University, Palo Alto, CA). Fractionation of proteins into Triton X-100-soluble and -insoluble fractions was performed as previously described (Sadot et al., 2001) , and equal volumes of lysates from the two fractions were analysed. Western blots were developed using the ECL method (Amersham).
Immunofluorescence microscopy
Cells were cultured on glass coverslips covered with poly-Llysine, fixed with 3% paraformaldehyde in PBS for 20 min at room temperature and permeabilized with 0.5% Triton X-100 in PBS for 3 min. The coverslips were incubated with monoclonal anti-HA clone 12CA5 antibodies (Boehringer Mannheim), polyclonal anti-phospho-b-catenin (Thr41/Ser45) (Cell Signaling) and polyclonal anti-Axin antibodies (against the NH 2 terminus) obtained from Dr K Willert and R Nusee (see above). The secondary antibodies were Cy3-conjugated goat anti-mouse or anti-rabbit immunoglobulin G (Jackson Immuno-Research Laboratories).
